文献速递放射性药物与辐射防护肿瘤 PET/CT

成人中[18F]Me4FDG PET放射性示踪剂的安全性、生物分布与辐射剂量的体内评估

In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults.
PubMed 文献 · EJNMMI Res · 2024-05-15

本研究在5名健康志愿者(1男4女)中评估了靶向钠-葡萄糖共转运蛋白的PET示踪剂[18F]Me4FDG的安全性、生物分布与辐射剂量,注射活度为(2.4 ± 0.1)MBq/kg。结果显示所有志愿者耐受良好、无不良事件,有效剂量为(0.013 ± 0.003)mSv/MBq,肾脏吸收剂量最高(每肾0.05 mSv/MBq),脑几乎无摄取。作者认为该示踪剂似乎安全且生物分布良好,适用于PET成像及多次连续扫描。

要点

  • 5名健康志愿者均良好耐受[18F]Me4FDG,未报告不良事件。
  • 有效剂量为(0.013 ± 0.003)mSv/MBq,肾脏吸收剂量最高,每肾0.05 mSv/MBq。
  • 脑几乎无摄取,注射后60分钟(12 ± 15)%的给药剂量排泄入膀胱。

核心结论

  • 作者认为,[18F]Me4FDG有效剂量仅为(0.013 ± 0.003)mSv/MBq且无副作用发生,似乎是一种安全的放射性示踪剂,生物分布良好,适用于PET成像及多次连续扫描。

研究设计与样本

  • 本研究为体内评估研究,纳入5名健康志愿者(1名男性、4名女性)。
  • 志愿者接受多次全身PET/CT检查,从注射开始至注射后4小时,平均给药活度为(2.4 ± 0.1)MBq/kg(范围2.3-2.5 MBq/kg)。
  • PET/CT扫描分5次单独进行,扫描前及注射后1小时测量血压和体温并采集血、尿样本以评估毒性。
  • 感兴趣器官的[18F]Me4FDG放射性在5个时间点由PET/CT扫描测定,内剂量学采用快速蒙特卡罗方法在体素水平进行。
  • 试验注册号为NCT03557138,注册日期2017年2月22日。

主要发现

  • 所有受试志愿者均良好耐受[18F]Me4FDG,未报告不良事件。
  • 计算的有效剂量为(0.013 ± 0.003)mSv/MBq。
  • 吸收剂量最高的器官为肾脏,每肾0.05 mSv/MBq。
  • 脑几乎无摄取。
  • 注射后60分钟,(12 ± 15)%的给药剂量排泄入膀胱。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approaches targeting the sodium-glucose cotransporter (SGLT) could represent a promising future therapeutic strategy for numerous oncological and metabolic diseases. In this study, we evaluated the safety, biodistribution and radiation dosimetry of the glucose analogue positron emission tomography (PET) agent [18F] labeled alpha-methyl-4-deoxy-4-[18F]fluoro-D-glucopyranoside ([18F]Me4FDG) with high sodium-glucose cotransporter and low glucose transporter (GLUT) affinity. For this purpose, five healthy volunteers (1 man, 4 women) underwent multiple whole-body PET/computed tomography (CT) examinations starting with injection and up to 4 h after injection of averaged (2.4 ± 0.1) MBq/kg (range: 2.3-2.5 MBq/kg) administered activity. The PET/CT scans were conducted in 5 separate sessions, blood pressure and temperature were measured, and blood and urine samples were collected before the scans and one hour after injection to assess toxicity. Measurements of [18F]Me4FDG radioactivity in organs of interest were determined from the PET/CT scans at 5 time points. Internal dosimetry was performed on voxel level using a fast Monte Carlo approach. RESULTS: All studied volunteers could well tolerate the [18F]Me4FDG and no adverse event was reported. The calculated effective dose was (0.013 ± 0.003) mSv/MBq. The organs with the highest absorbed dose were the kidneys with 0.05 mSv/MBq per kidney. The brain showed almost no uptake. After 60 min, (12 ± 15) % of the administered dose was excreted into the bladder. CONCLUSION: Featuring an effective dose of only 0.013 ± 0.003 mSv/MBq and no occurrence of side effects, the glucose analogue [18F]Me4FDG seems to be a safe radio-tracer with a favorable biodistribution for PET imaging and also within several consecutive scans. TRIAL REGISTRATION NUMBER: NCT03557138, Registered 22 February 2017, https://ichgcp.net/clinical-trials-registry/NCT03557138 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Geist BK, Ramirez JC, Binder P, et al. In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults. EJNMMI Res. 2024. PMID: 38750398. doi:10.1186/s13550-024-01098-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。